Neurosurgeon Dr. Ben Rapoport, the cofounder of Precision Neuroscience, debunks the biggest misconception about invasive ...

Jazz Pharmaceuticals faced a challenging first quarter as revenue remained flat year over year, missing Wall Street expectations. Management attributed the performance to contrasting trends across its ...

Pre-formed fibrils (PFFs) are novel tools for modeling neurodegenerative diseases in neuroscience research. Generated in vitro, these fibrils can imitate endogenous protein aggregation in both animal ...

Nevertheless, in the near term Shire's neuroscience products will remain highly profitable, and Vyvanse is still forecast to be its top seller in 2022, ...

To meet this growing demand, we are proud to offer a series of high-quality Tau-related products to support researchers studying neurodegenerative diseases. Tau Protein: We offer full-length Tau, ...

Medtronic said steady demand for its cardiovascular and neuroscience products boosted revenue in its fiscal third quarter, though the top line was below analyst forecasts. The medical-technology ...

Alkermes has a portfolio of commercialized neuroscience products and a pipeline that spans both neuroscience and cancer. The drugmaker is now exploring the possibility of splitting off its cancer ...

Precision Neuroscience is building a modern alternative that’s not only an order of magnitude better, but far less invasive to put in. With a newly raised $41 million in the bank, ...

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, ... Provide specific products and services to you, such as portfolio management or data aggregation.

In recent years, the integration of neuroscience principles into business practices has gained significant attention due to its remarkable results. For example, companies that adopt neuroscience ...

Neurotech startup Precision Neuroscience on Thursday announced that a core component of its brain implant system has been approved by the U.S. Food and Drug Administration, a major win for the ...

AbbVie demonstrated a strong start to 2025, driven by robust growth in Skyrizi, Rinvoq, and neuroscience products, and raised its full-year EPS and revenue guidance.